AMO Pharma Announces Initiation of Pivotal REACH-CDM Clinical Trial for AMO-02 in Treatment of Congenital Myotonic Dystrophy

Bill Berry
Berry & Company Public Relations
212.253.8881
bberry@berrypr.com Related Links http://www.amo-pharma.com SOURCE AMO Pharma Limited
